-
POSTER
Efavirenz Is a Significant Inducer of Simvastatin and Atorvastatin
Metabolism:
Results of ACTG A5108 Study
JG Gerber, CJ Fichtenbaum, S Rosenkranz et al
 PDF
Poster
Abstract
-
POSTER
Sex and Weight as Covariates in the Pharmacokinetics of Efavirenz,
Indinavir, a
nd Nelfinavir
J Hitti, S Rosenkranz, S Cohn, et al
PDF
Poster
Abstract
-
POSTER
Mutations at Codon 135 at Baseline Are Associated with the Accumulation of
NNRTI-resistance Mutations while on EFV-containing Regimens
C Vavro, A Florance, D Irlbeck
PDF
Poster
Abstract
-
Virologic Failure in Antiretroviral Therapy Naive Patients Is
Only Determined by Extreme
Low Values of CD4+ Cells or High Values of
HIV-1 RNA Concentration, Not by Choice of
Treatment with Nevirapine or Efavirenz
F van Leth, S Andrews, B
Grinsztjen, et al
Abstract
-
Nevirapine- vs Efavirenz-based Antiretroviral Treatment in Naive Indian
patients:
Comparision of Effectiveness in a Clinical Cohort
AK Patel, S Pujari, KK Patel,
et al.
Abstract
-
Efavirenz Suppress the Rate of Viral Replication in Human
Brain Tissue Infected
with Zidovudine-resistant HIV
A Kandanearatchi, A
Vyakarnam, IP Everall,
Abstract
-
Lithium Improves HIV-associated Neurocognitive Impairment
S Letendre, S Woods, R Ellis,
et al.
Abstract
NARC007: Clinical Validation of the AACTG NeuroScreen
R Ellis, K Robertson, L Moo,
et al.
Abstract
-
Stop Study:
After Discontinuation of Efavirenz, Plasma Concentrations May Persist
for 2
Weeks or Longer
S Taylor, S Allen, S Fidler, et al
Abstract
-
Relationships
between Efavirenz Pharmacokinetics, Side Effects, Drug Discontinuation,
Virologic Response, and Race: Results from ACTG A5095/A5097s
H Ribaudo, D Clifford, R Gulick, et al
Abstract
-
A Common
CYP2B6 Variant Is Associated with Efavirenz Pharmacokinetics and Central
Nervous System Side Effects: AACTG Study NWCS214
D Haas, H Ribaudo, R Kim, et al
Abstract
-
Low-frequency NNRTI-resistant Variants Contribute to Failure of
Efavirenz-containing Regimens
J Mellors, S Palmer, D
Nissley, et al
Abstract-
A Genotypic Score for Efavirenz Hypersusceptibility Is Associated
with Virologic Response to
EFV + Indinavir +/- Abacavir in
Nucleoside-experienced Patients
L Demeter, V DeGruttola, S Lustgarten, et al
Abstract
-
ACTG 5097s: IMPACT OF EFAVIRENZ (EFV) ON NEUROPSYCHOLOGICAL
PERFORMANCE,
MOOD, AND SLEEP BEHAVIOR IN HIV-POSITIVE INDIVIDUALS
DB Clifford, S. Evans, Y. Yang, E. Acosta, et al
Abstract
-
DURABILITY OF EFAVIRENZ COMPARED TO NEVIRAPINE WITH LONG TERM
FOLLOW-UP
OF AN ANTIRETROVIRAL-NAIVE PATIENT COHORT
G. Matthews, Y. Gileece, S. Mandalia, et al
Abstract
-
EFFICACY, SAFETY, AND PHARMACOKINETICS OF EFAVIRENZ (EFV) 800 MG QD
CO-
ADMINISTRATED WITH RIFAMPIN (R) IN HIV-INFECTED PATIENTS WITH
TUBERCULOSIS
LF. López-Cortés, R. Ruiz-Valderas, J. Ruiz, et al
Abstract
-
EFAVIRENZ, RIFAMPICIN AND RIFABUTIN - A CASE FOR THERAPEUTIC DRUG
MONITORING?
P. Lewthwaite, S. Gibbons, F.J. Vilar, S.H. Khoo
-
AMBULATORY EEG AND THERAPEUTIC DRUG MONITORING IN THE MANAGEMENT OF
EFAVIRENZ-RELATED INSOMNIA
P. Barreiro, L. Gallego, R. del Río, et al
Abstract
-
SHORT-TERM TOLERANCE OF EFAVIRENZ IN HIV-INFECTED AFRICAN ADULTS
PARTICIPATING
IN THE TRIVACAN ANRS 1269 TRIAL, ABIDJAN, CÔTE D’IVOIRE
C. Danel, R. Moh, E. Messou, A. Minga, et al
Abstract
-
HIGHER EFAVIRENZ PLASMA LEVELS ALLOW TO REGAIN COMPLETE VIRAL
SUPPRESSION
IN PATIENTS WITH EFZ-ASSOCIATED RESISTANCE MUTATIONS
D. González de Requena, O. Gallego, I. Jimenez-Nácher, V. Soriano
Abstract
-
STANDARD DOSES OF EFAVIRENZ (EFV), ZIDOVUDINE (ZDV), TENOFOVIR
(TDF), AND
DIDANOSINE (ddI) MAY BE GIVEN WITH TIPRANAVIR/RITONAVIR (TPV/r)
P.J. Roszko, K. Curry, B. Brazina, et al
Abstract
-
ATAZANAVIR AND EFAVIRENZ HAVE SIMILAR EFFECTS ON BODY FAT
DISTRIBUTION IN
ANTIRETROVIRAL-NAÏVE PATIENTS WHEN COMBINED WITH FIXED-DOSE
ZIDOVUDINE AND
LAMIVUDINE: 48-WEEK RESULTS FROM THE METABOLIC SUBST
J.G. Jemsek, E. Arathoon, M. Arlotti, et al
Abstract
|
-
Treatment with a combination of Efavirenz , Nevirapine and NRTIs in HIV
patients
J A Arranz-Caso, M Gorgolas, V Estrada, J D García-Diaz
Abstract
-
The
SENC trial: a randomized, open-label study comparing efavirenz versus
nevirapine. Results
at
48 weeks
M Nunez, V Soriano, L Martin-Carbonero, et al
Abstract
-
I
ncidence of CNS effects in patients with a history of mental health
disorders and/or substance
abuse starting an efavirenz-containing regimen: Data from HAVACS
J L Guest, K E DeSilva, T D Flaherty, et al
Abstract
-
Efavirenz-based regimen in advanced AIDS with cryptococcal meningitis: A
prospective multicenter study
S Sungkanuparph, A Vibhagool, P Mootsikapun, et al
Abstract
-
HAART with efavirenz: metabolic and hepatic side effects
B Roca, J Garcia, M S Ruiz, C Lapuebla
Abstract
-
High
effectiveness of efavirenz-based HAART in HIV-1 infected patients with
less than 100 CD4 cells/mL
and opportunistic diseases. The EfaVIP-1 study
J R Arribas, F Pulido, J M Miró, et al
Abstract-
Sensio study: assessment of late neuropsychiatric adverse reactions (NPAR)
to efavirenz
P Lochet, H Peyriere, J M Mauboussin, et al
Abstract
-
Simultaneous HPLC measurement of efavirenz and rifampicin exposure in HIV+
patients with
tuberculosis
M Boffito, S Bonora, J Tija, P G Hoggard, et al
-
Absence of detectable viremia in semen of HIV-infected patients treated
with effective efavirenz-
containing antiretroviral regimen
G Liuzzi, M Zaccarelli, A Amendola, et al
Abstract
-
Comparative study of efavirenz or protease inhibitor-based HAART in
HIV-infected, antiretroviral naive
patients with
<100
CD4 cel/μL and opportunistic diseases (EFAVIP-2 study)
F Pulido, J R Arribas, J M
Miro, et al
Abstract
-
A
ntiretroviral
combination therapy containing NNRTI (efavirenz). Twenty-four weeks data
C Bussolino, M Palumbo, G Calcagno, et al
Abstract
-
Effect of efavirenz and nevirapine on P-gp expression: the impact on
protease inhibitor fluxing
L M Almond, B Chandler, P G Hoggard. et al
Abstract
-
Evaluation of toxicity and adverse events related to efavirenz (EFV) and
Nevirapine (NVP) containning
regimens in clinical practice
M Torralba, R Rubio, F Pulido, et al
-
Comparison of efavirenz and nevirapine in antiretroviral naive and
pretreated patients in a real world
setting
M Hartmann, A Rump, J Brust, et al
Abstract
-
Psychiatric symptomatology and utilization of mental health services among
patients using an
efavirenz-containing regimen(Sustiva), in an urban, out-patient HIV clinic
M E Theodore, V Guarino, H Wolfe, V Sharp
Abstract
-
Efavirenz does not affect Amprenavir exposure when co-administered with
Ritonavir in HIV-1+ subjects
R G Hewitt, D Cloen, T Olatinwo
Abstract
-
Efavirenz (STOCRIN™) Expanded Access Program
M Stek, K Patel, M Shivaprakash, J Menten
Abstract
-
A
randomized study of treatment simplification with nevirapine (NVP) or
efavirenz (EFV) in patients
responding to a protease inhibitor (PI) based combination
P Patterson, C Zala, A Krolewiecki, et al
Abstract
|
12th
CROI
XV
International AIDS Conference
11th
CROI
XIV
International AIDS Conference
Efavirenz
Conf. Main Page
Main
New/Newsworthy
